The estimated Net Worth of Frank Palantoni is at least $174 Tausend dollars as of 21 May 2023. Mr. Palantoni owns over 9,302 units of Lexicon Pharmaceuticals Inc stock worth over $68,161 and over the last 19 years he sold LXRX stock worth over $0. In addition, he makes $105,975 as Independent Director at Lexicon Pharmaceuticals Inc.
Frank has made over 4 trades of the Lexicon Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 9,302 units of LXRX stock worth $15,720 on 21 May 2023.
The largest trade he's ever made was exercising 10,638 units of Lexicon Pharmaceuticals Inc stock on 24 April 2021 worth over $17,978. On average, Frank trades about 885 units every 36 days since 2005. As of 21 May 2023 he still owns at least 40,332 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Mr. Palantoni stock trades at the bottom of the page.
Frank P. Palantoni serves as Independent Director of the Company. Mr. Palantoni has been a director since November 2004. Mr. Palantoni is chief executive officer of Laboratory M2, a clean technology company involved in animal health, crop protection and retail sectors. Mr. Palantoni was president of Palantoni & Partners LLC, an advisory firm for the consumer and health care industries, from 2013 to 2016. He previously served as president of the pet and animal health division of Central Garden & Pet Company, was a partner at P3 Capital Management LLC, an early stage consumer products equity fund, served as chief operating officer and chief executive officer of Prestige Brands Holding, Inc. and held a variety of senior management positions with Novartis AG, including president and chief executive officer, worldwide of the Gerber Products Company, and chief executive officer for North American operations of the Consumer Health Division. Prior to joining Novartis, he held a series of senior management positions with The Danone Group. He holds a B.S. from Tufts University and an M.B.A. from Columbia University.
As the Independent Director of Lexicon Pharmaceuticals Inc, the total compensation of Frank Palantoni at Lexicon Pharmaceuticals Inc is $105,975. There are 12 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.
Frank Palantoni is 62, he's been the Independent Director of Lexicon Pharmaceuticals Inc since 2004. There are 8 older and 11 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.
Frank's mailing address filed with the SEC is 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS, TX, 77381.
Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc... und Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: